Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

NCT01663727 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

481

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Bevacizumab [Avastin]
DRUG: Paclitaxel
DRUG: Placebo

Sponsor

Hoffmann-La Roche